

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2005-05-02** | Period of Report: **2005-05-02**
SEC Accession No. **0001176256-05-000159**

([HTML Version](#) on [secdatabase.com](#))

FILER

CHEMOKINE THERAPEUTICS CORP

CIK: **1092959** | IRS No.: **330921251** | State of Incorporation: **DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **000-51080** | Film No.: **05791968**
SIC: **2836** Biological products, (no diagnostic substances)

Mailing Address
6190 AGRONOMY ROAD,
SUITE 405
VANCOUVER A1 V6T 1Z3

Business Address
6190 AGRONOMY ROAD,
SUITE 405
VANCOUVER A1 V6T 1Z3
604-8220301

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 2, 2005

CHEMOKINE THERAPEUTICS CORP.

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction
of incorporation)

333-117858
(Commission
File Number)

33-0921251
(IRS Employer
Identification No.)

6190 Agronomy Road, Suite 405
Vancouver, British Columbia
(Address of principal executive offices)

V6T 1Z3
(Zip Code)

Registrant's telephone number, including area code **(604) 822-0301**

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01. Other Events.

On May 2, 2005, Chemokine Therapeutics Corp. (“the Registrant”) issued a press release that Dr. Hassan Salari, President and CEO, will be presenting at the Rodman and Renshaw Techvest 2nd Annual Conference in Paris, France on Thursday May 5, 2005.

ITEM 9.01. Financial Statements and Exhibits.

- a. Not applicable.
- b. Not applicable.
- c. Exhibits.

Exhibit Number	Description of Exhibit
99.1	Press Release of Registrant, dated May 2, 2005, announcing that Dr. Hassan Salari, President and CEO, will be presenting at the Rodman and Renshaw Techvest 2 nd Annual Conference in Paris, France on Thursday May 5, 2005.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Chemokine Therapeutics Corp.,
a Delaware corporation

Date: May 2, 2005

By: /s/ David Karp
David Karp
Chief Financial Officer and Corporate Secretary



EXHIBIT INDEX

Exhibit Number

Description of Exhibit

99.1 Press Release of Registrant, dated May 2, 2005, announcing that Dr. Hassan Salari, President and CEO, will be presenting at the Rodman and Renshaw Techvest 2nd Annual Conference in Paris, France on Thursday May 5, 2005.



FOR IMMEDIATE RELEASE

TSX symbol: CTI

**Chemokine Therapeutics to Present at Rodman & Renshaw
Techvest 2nd Annual Global Healthcare Conference**

Vancouver, BC (May 2, 2005) - Chemokine Therapeutics Corp. (Toronto Stock Exchange: CTI), a biotechnology company developing drugs in the field of chemokines and cytokines, today announced that Dr. Hassan Salari, President and CEO, will be presenting at the Rodman and Renshaw Techvest 2nd Annual Conference in Paris, France on Thursday May 5, 2005. Dr. Salari will provide an update on Chemokine Therapeutics' novel products and their potential for broad applications in cancer, immune system disorders, cardiovascular disease and peripheral vascular disease.

When: Thursday May 5th at 8:40 CEST / 2:40 EDT

How: The live broadcast of the presentation can be accessed through our website at www.chemokine.net. After the presentation date, the webcast will be archived on our website.

Hassan Salari, Ph.D.

Dr. Salari has a Ph.D. degree from the University of Southampton, UK, Department of Microbiology. Throughout his academic career, Dr. Salari has published over 150 scientific articles and book chapters on various immunology topics and autoimmune diseases. Dr. Hassan Salari has led Chemokine Therapeutics as Chairman, President and Chief Executive Officer since its inception July 1998.

About Chemokine Therapeutics Corp. (Toronto Stock Exchange: CTI)

Chemokine Therapeutics is a biotechnology company developing drugs in the field of chemokines and cytokines, a family of small, soluble proteins, which signal stem cell transport and growth into mature cells. These stem cells are master primitive cells, capable of producing billions of mature cells necessary for repair and regeneration. Chemokines and cytokines also play an important role in cancer and autoimmune disorders which can paradoxically contribute to the survival and growth of such diseases. The Company has two product candidates in clinical trials; CTCE-0214, for immune system recovery, and CTCE-9908, to prevent the spread of cancer and its continued growth. In addition, Chemokine maintains a drug discovery program to identify new chemokine-based drug candidates. Pharmaceutical Product Development, Inc. (PPDI) and Procter & Gamble Pharmaceuticals, Inc. have signed strategic agreements with Chemokine to collaborate on research and development. For more information, please visit our website at www.chemokine.net.

-30-

Chemokine Therapeutics Corp.

Ian Harper

Director of Investor Relations & Corporate Development

Phone: (604) 822-0305

E-mail: iharper@chemokine.net